Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 4:51 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 742 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Migraine Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Bioequivalency Study of Naratriptan Hydrochloride 2.5 mg Under Fed Conditions

NCT01161654
View directory record Official record
Conditions
Migraine
Interventions
naratriptan hydrochoride
Drug
Lead sponsor
Roxane Laboratories
Industry
Eligibility
18 Years to 45 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 20, 2026, 4:51 PM EDT
Not yet recruiting Not applicable Interventional

EMBRACE Study: Enduring Migraine Benefit From Responsive Artery Coil Embolization

NCT07313800
View directory record Official record
Conditions
Migraine Disorders, Refractory Migraine, Chronic Migraine
Interventions
TEMMA Endovascular Treatment
Device
Lead sponsor
Cortex Neurovascular
Industry
Eligibility
18 Years to 60 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2028 – 2032
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 20, 2026, 4:51 PM EDT
Completed Phase 2 Interventional Results available

Staccato Prochlorperazine in Migraine (Out Patient)

NCT00422812
View directory record Official record
Conditions
Migraine Headache, Aura
Interventions
Inhaled Placebo, Inhaled PCZ 5 mg, Inhaled PCZ 7.5 mg, Inhaled PCZ 10 mg
Drug
Lead sponsor
Alexza Pharmaceuticals, Inc.
Other
Eligibility
18 Years to 70 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
25
States / cities
Scottsdale, Arizona • San Francisco, California • Santa Monica, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2018 · Synced Oct 20, 2026, 4:51 PM EDT
Completed Phase 4 Interventional Results available

The CHECK Trial: A Comparison of Headache Treatment in the ED: Compazine Versus Ketamine

NCT02657031
View directory record Official record
Conditions
Headache
Interventions
Prochlorperazine, Ketamine, Diphenhydramine, Ondansetron, Normal Saline
Drug
Lead sponsor
University Medical Center of Southern Nevada
Other
Eligibility
18 Years to 65 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Dec 11, 2017 · Synced Oct 20, 2026, 4:51 PM EDT
Completed Phase 2 Interventional

Study to Evaluate the Efficacy and Safety of Dronabinol Metered Dose Inhaler (MDI) in Acute Treatment of Migraine Headache

NCT00123201
View directory record Official record
Conditions
Migraine With Aura, Migraine Without Aura
Interventions
Dronabinol MDI
Drug
Lead sponsor
Solvay Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
29
States / cities
Huntsville, Alabama • Tucson, Arizona • Anaheim, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2015 · Synced Oct 20, 2026, 4:51 PM EDT
Terminated Phase 3 Interventional Results available

The Childhood and Adolescent Migraine Prevention Study

NCT01581281
View directory record Official record
Conditions
Migraine, Migraine Disorders, Headache
Interventions
Amitriptyline, Topiramate, Placebo
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
8 Years to 17 Years
Enrollment
488 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
35
States / cities
Phoenix, Arizona • San Francisco, California • Stanford, California + 32 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2017 · Synced Oct 20, 2026, 4:51 PM EDT
Withdrawn Phase 4 Interventional

Improving Health Outcomes of Migraine Patients Who Present to the Emergency Department

NCT02945839
View directory record Official record
Conditions
Migraine
Interventions
Preventative Medication (PM), Enhanced Usual Care, PMR (progressive muscle relaxation therapy)
Drug · Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 64 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 29, 2019 · Synced Oct 20, 2026, 4:51 PM EDT
Recruiting Not applicable Interventional

The Effect of Remote Electrical Neuromodulation (REN) on Conditioned Pain Modulation (CPM) in Migraine and Fibromyalgia

NCT07841509
View directory record Official record
Conditions
Migraine, Fibromyalgia, Conditioned Pain Modulation
Interventions
Remote Electrical Neuromodulation (REN) device
Device
Lead sponsor
Theranica
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 20, 2026, 4:51 PM EDT
Completed Phase 4 Interventional Results available

Valproate Versus Ketorolac Versus Metoclopramide

NCT01267864
View directory record Official record
Conditions
Acute Migraine
Interventions
Metoclopramide, Ketorolac, Valproate
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
21 Years to 64 Years
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jun 4, 2018 · Synced Oct 20, 2026, 4:51 PM EDT
Completed Not applicable Interventional

NYU Langone Health Headache Center Learning Migraine Self-Management Techniques Study

NCT06077812
View directory record Official record
Conditions
Migraine
Interventions
RELAXaHEAD Smartphone App, In-Person Training, Virtual Training
Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 16, 2024 · Synced Oct 20, 2026, 4:51 PM EDT
Completed Phase 3 Interventional

Headstrong Intervention for Pediatric Headache

NCT00269581
View directory record Official record
Conditions
Chronic Headaches
Interventions
Educational CD-rom, Headstrong CD-rom
Other
Lead sponsor
Michael Rapoff, Ph.D.
Other
Eligibility
7 Years to 12 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
2
States / cities
Kansas City, Kansas • Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 25, 2012 · Synced Oct 20, 2026, 4:51 PM EDT
Terminated Phase 3 Interventional

Efficacy and Safety of Cyclobenzaprine Hydrochloride Extended Release for the Treatment of Chronic Migraine

NCT01151787
View directory record Official record
Conditions
Chronic Migraine
Interventions
cyclobenzaprine hydrochloride, placebo
Drug
Lead sponsor
Kennedy Medical Group
Other
Eligibility
18 Years to 65 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Cherry Hill, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 25, 2014 · Synced Oct 20, 2026, 4:51 PM EDT
Completed Phase 2 Interventional Results available

A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study of Elismetrep (K-304) in the Treatment of Migraine

NCT06848075
View directory record Official record
Conditions
Migraine
Interventions
Elismetrep (K-304) 2 mg, Elismetrep (K-304) 5 mg, Elismetrep (K-304) 10 mg, Elismetrep (K-304) 20 mg, Placebo
Drug
Lead sponsor
Kallyope Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
431 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
66
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 20, 2026, 4:51 PM EDT
Terminated Not applicable Interventional Results available

A Research Study Examining the Use of Olanzapine for the Prevention of Migraine

NCT00203307
View directory record Official record
Conditions
Migraine
Interventions
Olanzapine during first intervention period and placebo during second intervention period, Placebo during first intervention period, then olanzapine during second intervention period
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 65 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 25, 2011 · Synced Oct 20, 2026, 4:51 PM EDT
Completed No phase listed Observational

Healthcare Costs and Resource Utilization in Aimovig Migraine Patients: a Retrospective Study Using United States Claims Data

NCT05177406
View directory record Official record
Conditions
Migraine
Interventions
Aimovig
Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
1,839 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 4, 2022 · Synced Oct 20, 2026, 4:51 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Analysis of Headache Chronification With Imaging, Deep Phenotyping, and Proteomics

NCT03231241
View directory record Official record
Conditions
Chronic Daily Headache, Chronic Migraine
Interventions
Not listed
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
700 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2026
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jul 23, 2025 · Synced Oct 20, 2026, 4:51 PM EDT
Completed Not applicable Interventional Results available

Cranial Electrotherapy Stimulation in the Treatment of Migraine Headaches

NCT01265797
View directory record Official record
Conditions
Migraine
Interventions
Cranial Electrostimulator, Sham Device
Device
Lead sponsor
University of Toledo Health Science Campus
Other
Eligibility
18 Years to 65 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Toledo, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 10, 2015 · Synced Oct 20, 2026, 4:51 PM EDT
Active, not recruiting Phase 3 Interventional

A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic Migraine

NCT07018713
View directory record Official record
Conditions
Chronic Migraine
Interventions
Xeomin, Placebo
Drug
Lead sponsor
Merz Therapeutics GmbH
Industry
Eligibility
18 Years and older
Enrollment
808 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
48
States / cities
Chandler, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 42 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 20, 2026, 4:51 PM EDT
Completed Phase 3 Interventional Results available

Atogepant for Prophylaxis of Migraine in Participants Who Failed Previous Oral Prophylactic Treatments.

NCT04740827
View directory record Official record
Conditions
Episodic Migraine
Interventions
Atogepant 60 mg, Placebo
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 80 Years
Enrollment
315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
26
States / cities
Colton, California • Encino, California • Los Alamitos, California + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 20, 2026, 4:51 PM EDT
Completed No phase listed Observational

Family Study of Affective and Anxiety Spectrum Disorders

NCT00071786
View directory record Official record
Conditions
Mood Disorders, Sleep Disorders, Migraine
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
7 Years to 120 Years
Enrollment
1,944 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 20, 2026, 4:51 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the PK and Safety of Single Doses of STS101, DHE Injection and Nasal Spray in Healthy Subjects

NCT05337254
View directory record Official record
Conditions
Migraine, Migraine With Aura, Migraine Without Aura
Interventions
Dihydroergotamine
Drug
Lead sponsor
Satsuma Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 20, 2022 · Synced Oct 20, 2026, 4:51 PM EDT
Completed No phase listed Observational

A Research Study To Compare Two Kinds Of Daily Headache

NCT00335803
View directory record Official record
Conditions
Migraine
Interventions
Not listed
Lead sponsor
Thomas Jefferson University
Other
Eligibility
14 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 23, 2009 · Synced Oct 20, 2026, 4:51 PM EDT
Recruiting Phase 3 Interventional

Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine

NCT04743141
View directory record Official record
Conditions
Acute Treatment of Migraine
Interventions
Rimegepant (PF-07899801)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
6 Years to 17 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
115
States / cities
Scottsdale, Arizona • Tempe, Arizona • Anaheim, California + 77 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 20, 2026, 4:51 PM EDT
Not listed Phase 3 Interventional

Buccal Prochlorperazine Versus Intravenous Prochlorperazine for Migraine Headaches, a RCT

NCT02779959
View directory record Official record
Conditions
Migraine Disorders
Interventions
Prochlorperazine
Drug
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Jan 5, 2018 · Synced Oct 20, 2026, 4:51 PM EDT